ONIVIX Trademark

Trademark Overview

On Friday, April 29, 2022, a trademark application was filed for ONIVIX with the United States Patent and Trademark Office. The USPTO has given the ONIVIX trademark a serial number of 97388974. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Wednesday, October 30, 2024. This trademark is owned by TEVA PHARMACEUTICALS USA, Inc.. The ONIVIX trademark is filed in the Medical Instrument Products category with the following description:

Contraceptive device, namely, an intrauterine device
onivix

General Information

Serial Number97388974
Word MarkONIVIX
Filing DateFriday, April 29, 2022
Status732 - THIRD EXTENSION - GRANTED
Status DateWednesday, October 30, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 21, 2023

Trademark Statements

Goods and ServicesContraceptive device, namely, an intrauterine device

Classification Information

International Class010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials.
US Class Codes026, 039, 044
Class Status Code6 - Active
Class Status DateWednesday, May 4, 2022
Primary Code010
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameTEVA PHARMACEUTICALS USA, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054
Party NameTEVA PHARMACEUTICALS USA, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Trademark Events

Event DateEvent Description
Thursday, February 2, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, May 3, 2022NEW APPLICATION ENTERED
Wednesday, May 4, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, July 7, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, July 7, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, July 7, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, February 2, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, February 2, 2023TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Thursday, February 2, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, February 15, 2023ASSIGNED TO EXAMINER
Thursday, February 16, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, March 21, 2023PUBLISHED FOR OPPOSITION
Tuesday, March 21, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, March 1, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, November 9, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, May 16, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, November 9, 2023SOU EXTENSION 1 FILED
Thursday, November 9, 2023SOU EXTENSION 1 GRANTED
Tuesday, April 30, 2024SOU TEAS EXTENSION RECEIVED
Saturday, November 11, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, April 30, 2024SOU EXTENSION 2 FILED
Wednesday, May 1, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, October 30, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, October 30, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, October 30, 2024SOU EXTENSION 3 GRANTED
Wednesday, October 30, 2024SOU EXTENSION 3 FILED
Tuesday, April 30, 2024SOU EXTENSION 2 GRANTED

Related Keywords

onivix device intrauterine namely contraceptive